Professor Tan Huay Cheem
MBBS, MMed (Int Med), FRCP (UK), FAMS, FACC, FSCAI
Director National University Heart Centre,Singapore (NUHCS)
Senior Consultant Department of Cardiology, NUHCS
Professor of Medicine Yong Loo Lin School of Medicine, NUS
Professor Tan Huay Cheem graduated from the National University of Singapore in 1987 and obtained his Masters of Medicine in Internal Medicine and Membership of Royal College of Physician (United Kingdom) in 1992.
He did his Interventional Cardiology fellowship at Duke University Medical Centre, North Carolina, USA in 1995. He received Fellowship of American College of Cardiology in 2001, Fellowship of Society of Coronary Angiography and Intervention in 2002 and Fellowship of Royal College of Physician in 2004. He also received Vascular Ultrasonography training at St Vincent’s Hospital, Sydney, Australia; and carotid stenting at Taiwan National University Hospital.
He is presently Senior Consultant Cardiologist at the National University Hospital. His concurrent appointments are Director, National University Heart Centre, Singapore and Professor, Yong Loo Lin School of Medicine, National University of Singapore.
Prof Tan is regularly invited as lecturer and faculty in many international cardiology meetings. He is also an active clinical researcher and is a visiting professor to several hospitals in China.
- Platelet glycoprotein IIb/IIIa integrin blockade in coronary artery disease: Current state of the art. Tan HC, RA Harrington, JE Tcheng. urnal of Thrombosis and Thrombolysis 1997;4:431-9.
- Treatment of Palmaz-Schatz In-stent restenosis: 6-Month Clinical Follow-up. Tan HC, Crowley J, Tcheng JE, Sng LW, Sketch Jr MH, Phillips HR, Stack RS , Zidar JP . J Intervent Cardiol 2000;13:315-22.
- Direct stenting compared to conventional stenting in diabetic patients undergoing elective angioplasty for coronary artery disease (DECIDE): A Multicentre, open-label, randomized, controlled efficacy study. Tan HC, Lim YT , Rosli TLA , Sim KH , Tan KH , Lee CH , Ismail O , Azman W . Heart Am J 2004; 148: 1007-1011.
- Predictors of bleeding complication and thrombocytopenia with the use of abciximab during percutaneous coronary intervention. Razakjr OA , Tan HC , Yip YL , Lim YT . J Intervent Cardiol 2005; 18:33-37.
- A Randomized, Double-Blind, Placebo-Controlled Trial of Abciximab for Prevention of In-Stent Restenosis in Diabetic Patients after Coronary Stenting: Results of the ASIAD (Abciximab in Stenting Inhibits restenosis Among Diabetics) Trial. Chen WH , Kaul U , Leung SK , Lau YK , Tan HC , Leung AW , Lee MK , Li SK , Ng W, Lee PY , Lam KF , Tse HF , Lau CP. J Invasive Cardiol. 2005; 10: 534-8.
- Outcomes after percutaneous coronary interventions in patients with chronic kidney disease. Tan HC. J Geriatric Cardiology 2005; 2: 183-7.
- Use of Endothelial Progenitor Cell Capture Stent (Genous Bio-Engineered R Stent) During Primary Percutaneous Coronary Intervention in Acute Myocardial Infarction: Intermediate to Long Term Clinical Follow-Up" Co M, Tay E, Lee CH , Poh KK , Low A , Lim J , Lim IH , Lim YT , Tan HC. Am Heart J 2008; 155: 128-132.
- Stent thrombosis after percutaneous coronary intervention for bifurcation lesion. Tan HC. J Interventional Cardiology 2009; 22: 114-116.
- Clinical Predictors of stent thrombosis in the “Real world” drug-eluting stent era. Tinhay EL , Poh KK , Lim YT, Low AFH , Lee CH , Teo SG , Lim J , Lim IH , Tan HC. International J Cardiology (in press).
- Endothelial progenitor cell capture stent implantation in patients with ST-segment acute myocardial infarction: one-year follow up. Lee YP , Tay E , Yeo WT , Lee CH , Low AFH , Poh KK , Teo SG , Lim IH , Lim YT , Tan HC. Eurointervention (in press).
For more publications, click here .
- Use of endothelial progenitor cell capture stent in patients with acute ST-segment myocardial infarction undergoing primary percutaneous coronary intervention.
- CONTRAST (Combined N-acetycysteine and bicarbonate in PCI To reduce adverse side effect of contrast)- a multicentre study
- Asian DIOR Registry (A multicentre registry with paclitaxel-elutingCoronary balloon to prevent restenosis)
- TRACER (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome)
- REMEDEE (Prospective randomized study to evaluate the safety and efficacy of an abluminal sirolimus-coated bioengineered stent (Combo bioengineered sirolimus eluting stent) compared with a Taxus Liberte stent control arm for treatment of stenotic lesions in native coronary arteries)
- CAT VI RCT (A multicentre randomsied controlled trial of Boomerang Catalyst VI System-Assisted Manual Compression vs manual compression alone for the management of the femoral arteriotomy after percutaneous intravascular procedures)
Back to Top